Particle size reduction

Water-Insoluble Drug Formulation, Second Edition

Volumn , Issue , 2008, Pages 467-498

  Lee, Robert W ^a   McShane, James ^b   Shaw, J Michael ^c   Wood, Ray W ^b   Shenoy, Dinesh B ^a  

^a NOVAVAX INC   (United States)

^b EISAI INC   (United States)

^c Elan Drug Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123269621     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (104)

1. Abdou, H. M. (1990) Dissolution, In Remington's Pharmaceutical Sciences, (A. R. Gennaro, ed.), pp. 589-602, Mack Publishing Co., Easton, PA.
2. Akers, M. J., Fites, A. L., and Robison, R. L. (1987) Formulation design and development of parenteral suspensions, J. Parenter. Sci. Technol., 41:88-96.
3. Allen, T. M. (1994) Long circulating (sterically stabilized) liposomes for targeted drug delivery, TIPS, 15:215-220.
4. Anderson, B. D. (1980) Thermodynamic considerations in physical property improvement through prodrugs, In Medicinal Research Series, Vol. 10: Physical Chemical Properties of Drugs, (S. H. Yalkowsky, A. A. Sinkula, and S. C. Valvani, eds.), pp. 231-266, Marcel Dekker, Inc., New York and Basel.
5. Aramwit, P., Kerdcharoen, T., and Qi, H. (2006) In vitro plasma compatibility study of a nanosuspension formulation, PDA J. Pharm. Sci. Technol., 60:211-217.
6. Blanton, T. N., Chatterjee, D. K., and Majumdar, D. (2002) Process for milling compounds, US Patent 6, 491, 239.
7. Borchard, G. and Kreuter, J. (1993) Interaction of serum components with poly(methyl methacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats, J. Drug Target., 1:15-93.
8. Braun, H. (1983) Particle size and solubility of disperse dyes, Rev. Prog. Coloration, 13:62-72.
9. Brunner, E. (1904) Reaktionsgeschwindigkeit in heterogenen Systemen, Z. Phys. Chem., 47:56-102.
10. Brunner, L. and Tolloczko, S. (1900) Uber die Auflosungsgeschwindigkeit fester Korper, Z. Phys. Chem., 35:283-290.
11. Burton, W.K., Cabrera, N., and Frank, F.C. (1951) The growth of crystals and the equilibrium structure of their surfaces, Phil. Trans. Roy. Soc., 243A:299-358.
12. Cammarata, A., Collett, J. H., and Tobin, E. (1980) Simultaneous determination of the solubility parameter, δ, and molar volume, V, for some para-substituted acetanilides in water, In Medicinal Research Series, Vol. 10: Physical Chemical Properties of Drugs, (S. H. Yalkowsky, A. A. Sinkula, and S. C. Valvani, eds.), pp. 267-276, Marcel Dekker, Inc., New York and Basel.
13. Canseleir, J. P. (1993) The effects of surfactants on crystallization phenomena, J. Disp. Sci. Technol., 14:625-644.
14. Chan, H. K. and Gonda, I. (1994) Shape modification of drug particles by crystallization, Proceedings of First International Particle Technology Forum, Vol. 3, pp. 174-179, Aug 17-19, 1994, American Institute of Chemical Engineers, Denver, NY.
15. Chaumeil, J. C. (1998) Micronization: A method of improving the bioavailability of poorly soluble drugs, Methods Find. Exp. Clin. Pharmacol., 20:211-215.
16. Czekai, D. A. and Seaman, L. P. (1999) Method of grinding pharmaceutical substances, US Patent 5, 862, 999.
17. Forssen, E. A. and Ross, M. E. (1994) Daunoxome registered treatment of solid tumors: preclinical and clinical investigations, J. Liposome Res., 4:481-512.
18. Garavilla, L. D., Peltier, N., and Merisko-Liversidge, E. (1996) Controlling the acute hemodynamic effects associated with IV administration of particulate drug dispersions in dogs, Drug Dev. Res., 37:86-96.
19. Gesler, R. M. and Garvin, P. J. (1973) The biological effects of polystyrene latex particles administered intravenously to rats, a collaborative study, Bull. Parent. Drug Assoc., 27:101-113.
20. Gonda, I. (2006) Systemic delivery of drugs to humans via inhalation, J. Aerosol. Med., 19:47-53.
21. Grant, D. J. W. and Chow, A. H.-L. (1991) Crystal modifications in acetaminophen by growth from aqueous solutions containing p-acetoxyacetanilide, a synthetic impurity, AIChE Symp. Ser., 284:33-37.
22. Grant, D. J. W. and Higuchi, T. (1990) Solubility behavior of organic compounds, In Techniques of Chemistry, Vol. XXI, (W. H. Saunders and A. Weissberger, eds.), Wiley-Interscience Publication, New York, NY.
23. Greco Macie, C. M. and Grant, D. J. W., (1986) Crystal growth in pharmaceutical formulation, Pharm. Int., 233-237.
24. Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., and Langer, R. (1994) Biodegradable long-circulating polymeric nanospheres, Science, 263:1600-1603.
25. Harwood, R. J., Portnoff, J. B., and Sunbery, E. W. (1993) The processing of small volume parenterals and related sterile products, In Pharmaceutical Dosage Forms: Parenteral Medications, (K. E. Avis, H. A. Lieberman, and L. Lachman, eds.), Vol. 2, pp. 42-51, Marcel Dekker, Inc., New York, NY.
26. Hernandez-Trejo, N., Kayser, O., Steckel, H., and Muller, R.H. (2005) Characterization of nebulized buparvaquone nanosuspensions-effect of nebulization technology, J. Drug Target, 13:499-507.
27. Hintz, R. J. and Johnson, K. C. (1989) The effect of particle size distribution on dissolution rate and oral absorption, Int. J. Pharm., 51:9-17.
28. Hixson, A. W. and Crowell, J. H. (1931) Dependence of reaction velocity upon surface and agitation. I. Theoretical considerations, Ind. Eng. Chem., 23:923-931.
29. Hunter, R. J. (1992) Foundations of Colloid Science, Vol. I, pp. 570-571, Oxford University Press, Oxford.
30. Idson, B. (1988) Pharmaceutical emulsions, Chap. 6, In Pharmaceutical Dosage Forms: Disperse Systems, (H.A. Lieberman, M. M. Rieger, and G. S. Banker, eds.), Vol. 1, pp. 199-243, Marcel Dekker, New York.
31. Ikekawa, A., Imagawa, K., Omori, T., and Kaneniwa, N. (1971) Influence of physicochemical properties on ball-milling of pharmaceutical powders, Chem. Pharm. Bull., 19:1027-1031.
32. Illum, L., Davis, S. S., Muller, R. H., Mak, E., and West, P. (1987) The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-polyoxamine 908, Life Sci., 40:367-374.
33. Illum, L., Davis, S. S., Wilson, C. G., Thomas, N. W., and Frier, M. (1982) Blood clearance and organ deposition of intravenously administered colloidal particles. Effects of particle size, nature and shape, Int. J. Pharm., 12:135-146.
34. Irngartinger, M., Camuglia, V., Damm, M., Goede, J., and Frijlink, H. W. (2004) Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing, Eur. J. Pharm. Biopharm., 58:7-14.
35. Jacobs, C. and Muller, R. H. (2002) Production and characterization of a budesonide nanosuspension for pulmonary administration, Pharm. Res., 19:189-194.
36. Juliano, R. L. (1988) Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions, Adv. Drug Deliv. Rev., 2:31-54.
37. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A. F., and Croft, S. L. (2003) Formulation of amphotericin B as nanosuspension for oral administration, Int. J. Pharm., 254:73-75.
38. Kocbek, P., Baumgartner, S., and Kristl, J. (2006) Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs, Int. J. Pharm., 312:179-186.
39. Kondo, N., Iwao, T., Masuda, H., Yamanouchi, K., Ishihara, Y., Yamada, N., Haga, T., Ogawa, Y., and Yokoyama, K. (1993) Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region, Chem. Pharm. Bull., 41:737-740.
40. Lantz, R. J. (1990) Size reduction. In Pharmaceutical Dosage Forms: Tablets, Vol. 2, (H. A. Lieberman, L. Lachman, and J. B. Schwartz, eds.), pp. 107-200, Marcel Dekker, Inc., New York, NY.
41. Lasic, D. (1993) Applications of liposomes in pharmacology and medicine, In Liposomes from Physics to Applications, pp. 262-471, Elsevier Press, Amsterdam.
42. Levy, G., Antkowiak, J. M., Procknal, J. A., and White, D. C. (1963) Effect of certain tablet formulation factors on dissolution rate of the active ingredient. II. Granule size, starch concentration, and compression pressure, J. Pharm. Sci., 52:1047-1051.
43. Lindfors, L., Forssen, S., Skantze, P., Skantze, U., Zackrisson, A., and Olsson, U. (2006a) Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations, Langmuir, 22:911-916.
44. Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M., Zackrisson, A., and Olsson, U. (2006b) Amorphous drug nanosuspensions. 1. Inhibition of ostwald ripening, Langmuir, 22:906-910.
45. Liversidge, G. G. and Conzentino, P. (1995) Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats, Int. J. Pharm., 125(2):309-313.
46. Liversidge, G. G., Cooper, E. R., Shaw, J. M., and McIntire, G. L. (1994) X-ray contrast compositions useful in medical imaging, US Patent 5, 318, 767.
47. Liversidge, G. G. and Cundy, K. C. (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, Int. J. Pharm. 125:91-97.
48. Liversidge, G. G., Cundy, K. C., Bishop, J. F., and Czekai, D. A. (1992) Surface modified drug nanoparticles, US Patent 5, 145, 684.
49. Lu, A. T. K., Frisella, M. E., and Johnson, K. C. (1993) Dissolution modeling: Factors affecting the dissolution rates of polydisperse powders, Pharm. Res., 10:1308-1314.
50. Mader, G. (1971) Determination of solubility, In Physical Methods in Chemistry Part V, (A. Weissberger and W. Bryant (eds.)), p. 259, Wiley-Interscience Publication, New York, NY.
51. Marino, F. J. (1993) Pharmaceutical suspensions, Chap. 8, In Pharmaceutical Dosage Forms: Parenteral Medications, (K. E. Avis, H. A. Lieberman, and L. Lachman, eds.), Vol. 2, pp. 187-189, Marcel Dekker, New York.
52. Mayer, L. D., Tai, L. C., Ko, S. C., Masin, D., Ginsberg, R. S., Cullis, P. R., and Bally, M. B. (1989) Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice, Cancer Res., 49:5922-5930.
53. McDonald, D. P. (1971) Micronization, Manuf. Chem. Aerosol News, May, 42:39-40.
54. Merisko-Liversidge, E., Liversidge, G. G., and Cooper, E. R. (2003) Nanosizing: A formulation approach for poorly-water-soluble compounds, Eur. J. Pharm. Sci., 18:113-120.
55. Merisko-Liversidge, E., Sarpotdar, P., Bruno, J., Hajj, S., Wei, L., Peltier, N., Rake, J., et al. (1996) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, Pharm. Res., 13:272-278.
56. Meyers, D. (1991) Surfaces, Interfaces, and Colloids, VCH Publishers, Inc., New York, NY.
57. Microfluidics (2005) Innovation through Microfluidizer® Processor Technology, MFIC Corporation, Newton, MA.
58. Moschwitzer, J., Achleitner, G., Pomper, H., and Muller, R. H. (2004) Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology, Eur. J. Pharm. Biopharm., 58:615-619.
59. Moschwitzer, J. and Muller, R. H. (2006) New method for the effective production of ultrafine drug nanocrystals, J. Nanosci. Nanotechnol., 6:3145-3153.
60. Mosharraf, M. and Nystrom, C. (2003) Apparent solubility of drugs in partially crystalline systems, Drug Dev. Ind. Pharm., 29:603-622.
61. Muller, R. H., Becker, R., Kruss, B., and Peters, K. (1999) Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution, US Patent 5, 858, 410.
62. Na, G. C. and Rajagopalan, N. (1994) Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization, US Patent 5, 346, 702.
63. Nernst, W. (1904) Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen, Z. Phys. Chem., 47:52-55.
64. Noyes, A. A. and Whitney, W. R. (1897) The rate of solution of solid substances in their own solutions, J. Am. Chem. Soc., 19:930-934.
65. Ostrander, K. D., Bosch, H. W., and Bondanza, D. M. (1999) An in vitro assessment of a nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization, Eur. J. Pharm. Biopharm., 48:207-215.
66. Ostwald, W. (1900) Über die vermeintliche Isomerie des rotten und gelben Quecksilberoxyds und die Oberflachenspannung fester Körper, Z. Phys. Chem., 34:495-503.
67. Parrot, E. L. (1974) Milling of pharmaceutical solids, J. Pharm. Sci., 63:813-829.
68. Patravale, V. B., Date, A.A., and Kulkarni, R. M. (2004) Nanosuspensions: A promising drug delivery strategy, J. Pharm. Pharmacol., 56:827-840.
69. PDR (2007) Physicians' desk reference, 61st ed., Product Information on Injectables, pp. 401-3534, Thompson PDR, Montvale, NJ.
70. Peters, K., Leitzke, S., Diederichs, J. E., Borner, K., Hahn, H., Muller, R. H., and Ehlers, S. (2000) Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection, J. Antimicrob. Chemother., 45:77-83.
71. Pouton, C. W. (2006) Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system, Eur. J. Pharm. Sci., 29:278-287.
72. Rabinow, B. E. (2004) Nanosuspensions in drug delivery, Nat. Rev. Drug Discov., 3:785-796.
73. Ragnarsson, G., Sandberg, A., Johansson, M. O., Lindstedt, B., and Sjogren, J. (1992) In vitro release characteristics of a membrane-coated pellet formulation-influence of drug solubility and particle size, Int. J. Pharm., 79:223-232.
74. Rasenack, N. and Muller, B. W. (2002) Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs, Pharm. Res., 19:1894-1900.
75. Rasenack, N. and Muller, B.W. (2004) Micron-size drug particles: Common and novel micronization techniques, Pharm. Dev. Technol., 9:1-13.
76. Rasenack, N., Steckel, H., and Muller, B. W. (2003) Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process, J. Pharm. Sci., 92:35-44.
77. Rodriguez-Hornedo, N. and Wu, H.-J. (1991) Crystal growth kinetics of theophylline monohydrate, Pharm. Res., 8(5):643-648.
78. Ross, S. and Morrison, I. D. (1988) Colloidal Systems and Interfaces, John Wiley & Sons, Inc., New York, NY.
79. Ruddy, S. B. and Eickhoff, W. M. (1996) Isolation of ultra small particles, US Patent Number 5, 503, 723.
80. Ruddy, S. B., Merisko-Liversidge, E., Wong, S. M., Eickhoff, W. M., Roberts, M. E., Liversidge, G. G., Peltier, N., et al. (1995) Conference on Pharmaceutical Science and Technology, Fine Particle Society Meetings, August 24, Chicago, IL.
81. Schwarz, C., Mahnert, W., Lucks, J. S., and Muller, R. H. (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery I. Production, characterization and sterilization, J. Control. Rel., 30:83-96.
82. Setnikar, I. (1977) Micronization in pharmaceutics and in specifications of pharmacopoeas, Boll. Chim. Farm., 116:393-401.
83. Sokoloski, T. D. (1990) Solutions and phase equilibria, In Remington's Pharmaceutical Sciences, (A. R. Gennaro, ed.), pp. 207-227, Mack Publishing Co., Easton, PA.
84. Stehr, N. (1988) Recent developments in stirred ball milling, Int. J. Mineral Process., 22:431-444.
85. Stehr, N. and Schewdes, J. (1983) Investigation of the grinding behavior of a stirred ball mill, Ger. Chem. Eng., 6:337-343.
86. Tawashi, R. (1968) The dissolution rates of crystalline drugs, J. Mond. Pharm., 4:371-379.
87. Tice, R., Mason, D. W., and Gilley, R. M. (1989) Clinical use and future of parenteral microsphere delivery systems, Chap. 21, In Novel Drug Delivery and Its Therapeutic Application, (L. F. Prescott and W. S. Nimmo, eds.), pp. 223-225, John Wiley & Sons, New York, NY.
88. Tomlinson, E. (1987) Biological opportunities for site-specific drug delivery using particulate carriers, Chap. 2, In Drug Delivery Carriers, (P. Johnson and J. G. Lloyd-Jones, eds.), pp. 32-66, Ellis Horwood, Chichester, England.
89. Troster, S. D., Muller, U., and Kreuter, J. (1990) Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants, Int. J. Pharm., 61:85-100.
90. USP 26/NF 21 (2003) The United States Pharmacopeia, pp. 1963-1966, United States Pharmacopeial Convention, Inc., Rockville, MD.
91. Valvani, S. C. and Yalkowsky, S. H. (1980) Solubility and partitioning in drug design, In Medicinal Research Series, Vol. 10: Physical Chemical Properties of Drugs, (S. H. Yalkowsky, A. A. Sinkula, and S. C. Valvani, eds.), pp. 201-230, Marcel Dekker, Inc., New York and Basel.
92. Verhoff, F. H., Snow, R. A., and Pace, G. W. (2003) Media milling, US Patent 6, 604, 698.
93. Watari, N., Hanano, M., and Kaneniwa, N. (1980) Dissolution of slightly soluble drugs. VI. Effect of particle size of sulfadimethoxine on the oral bioavailability, Chem. Pharm. Bull., 28:2221-2225.
94. Wiedmann, T. S., Wood, R. W., and Decastro, L. (1996) Aerosols containing beclomethasone nanoparticle dispersions, WO/1996/025919, PCT/US1996/002347.
95. Wilkins, J. (1995) Aseptic filling in a rigid isolator at evans medical, Chap. 15, In Isolator Technology, (C. M. Wagner and J. E. Akers, eds.), pp. 293-301, Interpharm Press, Inc, Buffalo Grove, IL.
96. Wolf, G. L. and Gazelle, G. S. (1993) Current status of radiographic contrast media, Invest. Radiol., 28:S2-S4.
97. Wood, R. W., Clemente, W., Lambert, McShane, J. (1995) Single Dose Pharmacokinetic Comparison of Oral Phenytoin Administered as a Novel Nanocrystal Dispersion, Dilantin-125 Suspension or Dilantin Kapseals, 24th Annual Meeting ACCP.
98. Yao, J. H. and Laradji, M. (1993) Dynamics of ostwald ripening in the presence of surfactants, Phys. Rev. E., 47:2695-2701.
99. Yonezawa, Y., Kawase, S., Sasaki, M., Shinohara, I., and Sunada, H. (1995) Dissolution of solid dosage form. V. New form equations for non-sink dissolution of a monodisperse system, Chem. Pharm. Bull, 43:304-310.
100. Yonezawa, Y., Shinohara, I., Sasaki, M., Otsuka, A., and Sunada, H. (1994) Dissolution of solid dosage form. IV. Equation for non-sink dissolution of a monodisperse system, Chem. Pharm. Bull, 42:349-353.
101. Zheng, J. and Bosch, H. W. (1995) Sterile filtration of nanoparticulate drug formulations, 37th Annual Int. Industrial Pharmaceutical Research and Development Conference, June 5-9, Merrimac, WI.
102. Ziller, K. H. and Rupprecht, H. H. (1990) Control of crystal growth in drug suspensions, Pharm. Ind., 52:1017-1022.
103. Zipp, G. L. and Rodriguez-Hornedo, N. (1989) Determination of crystal growth kinetics from desupersaturation measurements, Int. J. Pharm., 51:147-156.
104. Zografi, G., Schott, H., and Swarbrick, J. (1990) Disperse systems, In Remington's Pharmaceutical Sciences, (A. R. Gennaro, ed.), pp. 257-309, Mack Publishing Co., Easton, PA.